Suppr超能文献

Compritol 888 ATO基质烧结效果的机制评估。

Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices.

作者信息

Rao Monica, Ranpise Anuradha, Borate Sameer, Thanki Kaushik

机构信息

Department of Pharmaceutics, AISSMS College of Pharmacy, Kennedy Road, Near RTO, Pune-01, Maharastra, India.

出版信息

AAPS PharmSciTech. 2009;10(2):355-60. doi: 10.1208/s12249-009-9211-8. Epub 2009 Mar 31.

Abstract

The present research studied the effect of sintering technique in the development of a controlled release formulation for ketorolac tromethamine. The method consisted of mixing drug and wax powder (Compritol 888 ATO) along with lactose as diluent and talc as lubricant followed by direct compression at room temperature. The compressed fluffy matrices were kept at 80 degrees C for 1, 2, and 3 h for sintering. The sintered tablets were characterized by their physical parameters and in vitro dissolution profile. The sintering time markedly affected the drug release properties of Compritol 888 ATO matrices. It is notable that the release rate of ketorolac tromethamine from matrices was inversely related to the time of sintering. This may be due to the increase in the extent and firmness of sintering which further compacts the mass so that drug release is affected. Contact angle measurement and scanning electron microscopy analysis indicated that heat treatment caused the wax to melt and redistribute. This redistributed wax formed a network-like structure in which the drug along with lactose is entrapped. This particular formed matrix is responsible for retarding the drug release. Fourier transform infrared spectroscopy results did not show any drug-wax interaction due to sintering. Differential scanning calorimetric and powder X-ray diffraction studies ruled out the occurrence of solid solution and polymorphic changes of the drug. Drug release from the wax tablets with or without sintering was best described by the Higuchi equation.

摘要

本研究考察了烧结技术在制备酮咯酸氨丁三醇控释制剂中的作用。方法包括将药物与蜡粉(Compritol 888 ATO)、乳糖作为稀释剂以及滑石粉作为润滑剂混合,然后在室温下直接压片。将压制的蓬松基质在80℃下保持1、2和3小时进行烧结。通过物理参数和体外溶出曲线对烧结片剂进行表征。烧结时间显著影响Compritol 888 ATO基质的药物释放特性。值得注意的是,酮咯酸氨丁三醇从基质中的释放速率与烧结时间呈负相关。这可能是由于烧结程度和牢固性的增加进一步压实了物料,从而影响了药物释放。接触角测量和扫描电子显微镜分析表明,热处理导致蜡熔化并重新分布。这种重新分布的蜡形成了一种网络状结构,药物和乳糖被困在其中。这种特殊形成的基质负责延缓药物释放。傅里叶变换红外光谱结果未显示由于烧结而产生的任何药物 - 蜡相互作用。差示扫描量热法和粉末X射线衍射研究排除了药物固溶体和多晶型变化的发生。含或不含烧结的蜡片的药物释放最好用Higuchi方程描述。

相似文献

1
Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices.
AAPS PharmSciTech. 2009;10(2):355-60. doi: 10.1208/s12249-009-9211-8. Epub 2009 Mar 31.
2
Effect of processing and sintering on controlled release wax matrix tablets of ketorolac tromethamine.
Indian J Pharm Sci. 2009 Sep;71(5):538-44. doi: 10.4103/0250-474X.58188.
6
In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
Int J Pharm. 2006 Nov 6;324(2):152-7. doi: 10.1016/j.ijpharm.2006.06.006. Epub 2006 Jun 9.
8
Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets.
Expert Opin Drug Deliv. 2013 Jan;10(1):33-45. doi: 10.1517/17425247.2013.743528. Epub 2012 Nov 30.
9
Melt granulation and heat treatment for wax matrix-controlled drug release.
Drug Dev Ind Pharm. 2003 Feb;29(2):131-8. doi: 10.1081/ddc-120016720.
10
Non-destructive methods of characterization of risperidone solid lipid nanoparticles.
Eur J Pharm Biopharm. 2010 Sep;76(1):127-37. doi: 10.1016/j.ejpb.2010.05.003. Epub 2010 May 12.

引用本文的文献

2
The role of lipid particle-laden interfaces in regulating the co-delivery of two hydrophobic actives from o/w emulsions.
Drug Deliv. 2024 Dec;31(1):2425158. doi: 10.1080/10717544.2024.2425158. Epub 2024 Nov 8.
3
Preparation and characterization of 3D printed PLA microneedle arrays for prolonged transdermal drug delivery of estradiol valerate.
Drug Deliv Transl Res. 2022 May;12(5):1195-1208. doi: 10.1007/s13346-021-01006-4. Epub 2021 May 22.
4
Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.
Pharm Res. 2015 May;32(5):1519-45. doi: 10.1007/s11095-015-1661-y. Epub 2015 Mar 19.
5
Solid lipid budesonide microparticles for controlled release inhalation therapy.
AAPS J. 2009 Dec;11(4):771-8. doi: 10.1208/s12248-009-9148-6. Epub 2009 Nov 12.

本文引用的文献

1
Sintering of wax for controlling release from pellets.
AAPS PharmSciTech. 2007 Sep 14;8(3):E74. doi: 10.1208/pt0803074.
3
Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC.
J Microencapsul. 2006 Jun;23(4):417-33. doi: 10.1080/02652040600612439.
4
Mechanistic evaluation of the effect of thermal-treating on Eudragit RS matrices.
Farmaco. 2005 Nov-Dec;60(11-12):925-30. doi: 10.1016/j.farmac.2005.07.009. Epub 2005 Oct 11.
6
Thermal treating as a tool for sustained release of indomethacin from Eudragit RS and RL matrices.
Int J Pharm. 2002 Oct 10;246(1-2):171-7. doi: 10.1016/s0378-5173(02)00378-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验